Skip to main content

Advertisement

Table 1 Patient and tumor characteristics and pattern of failure

From: Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study

Variables SIB group SeqB group Total p-value
Pts N (%) Pts N (%) Pts N (%)  
Sex
Female 64 (73.6) 76 (73.8) 140 (73.7) 0.9722
Male 23 (26.4) 27 (26.2) 50 (26.3)  
Median age (range) 64 (55–70) 62 (53–77) 63 (53–77) a0.4471
Subsite
Anal canal 73 (83.9) 80 (77.7) 153 (80.5) <.0001
Anal margin 14 (16.1) 23 (22.3) 37 (19.5)  
Histologic type
Basaloid 7 (8.0) 7 (6.8) 14 (7.4) 0.7425
Squamous cell 80 (92.0) 96 (93.2) 176 (92.6)  
Grading
NA 2 (2.4) 19 (18.4) 21 (11.1)  
G1 7 (8.0) 28 (27.2) 35 (18.4) 0.0003
G2 57 (65.5) 39 (37.9) 96 (50.5)  
G3 21 (24.1) 17 (16.5) 38 (20.0)  
T stage
T1 5 (5.8) 4 (3.9) 9 (4.7) 0.0725
T2 55 (63.2) 57 (55.3) 112 (59.0)  
T3 23 (26.4) 25 (24.3) 48 (25.3)  
T4 4 (4.6) 17 (16.5) 21 (11.0)  
N stage
N0 57 (65.5) 53 (51.5) 110 (57.9) 0.0015
N1 5 (5.8) 17 (16.5) 22 (11.6)  
N2 21 (24.1) 15 (14.6) 36 (18.9)  
N3 4 (4.6) 18 (17.4) 22 (11.6)  
Global stage
I 5 (5.7) 3 (2.9) 8 (4.2) 0.0730
II 49 (56.3) 44 (42.7) 93 (48.9)  
IIIA 8 (9.3) 21 (20.4) 29 (15.3)  
IIIB 25 (28.7) 35 (34.0) 60 (31.6)  
Inguinal node involv.
NA 0 (0%) 1 (1) 1 (0.6) 0.0187
Yes 18 (20.7) 37 (35.9) 55 (28.9)  
No 69 (79.3) 65 (63.1) 134 (70.5)  
Time biopsy-RT (days)
  ≥ 60 62 (71.3) 5 (4.9) 67 (35.3) 0.0172
  < 60 25 (28.7) 98 (95.1) 123 (64.7)  
OTT (days)
  < 45 62 (71.3) 5 (4.9) 67 (35.3) <.0001
  ≥ 45 25 (28.7) 98 (95.1) 123 (64.7)  
  1. aU-Mann Whitney Test
  2. Legend: SIB simultaneous integrated boost, SeqB sequential boost, pts patients, N: number; involv.: Involvement, RT radiotherapy; OTT overall treatment time